UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial

The Lancet infectious diseases, 2013, Vol.13 (1), p.27-35

2013

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions

Antimicrobial Agents and Chemotherapy, 2012-01, Vol.56 (1), p.446-457

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization

Antimicrobial Agents and Chemotherapy, 2011-10, Vol.55 (10), p.4619-4630

2011

Link zum Volltext

Verfügbarkeit prüfen

Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example

Journal of medicinal chemistry, 2015-12, Vol.58 (23), p.9287-9295

2015

Link zum Volltext

Verfügbarkeit prüfen

Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus

Antimicrobial Agents and Chemotherapy, 2011-02, Vol.55 (2), p.649-658

2011

Link zum Volltext

Verfügbarkeit prüfen

Kinase Inhibitors of Marine Origin

Chemical reviews, 2013-08, Vol.113 (8), p.6761-6815

2013

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and assessment of a maleimide functionalized BF2 azadipyrromethene near-infrared fluorochrome

Chemical communications (Cambridge, England), 2015-12, Vol.51 (93), p.16667-16670

2015

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetic and Concentration-QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies

Journal of clinical pharmacology, 2011-08, Vol.51 (8), p.1152-1162

2011

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics of Levofloxacin, Gatifloxacin, and Moxifloxacin in Adults with Pulmonary Tuberculosis

Antimicrobial Agents and Chemotherapy, 2008-03, Vol.52 (3), p.852-857

2008

Link zum Volltext

Verfügbarkeit prüfen

Activities of High-Dose Daptomycin, Vancomycin, and Moxifloxacin Alone or in Combination with Clarithromycin or Rifampin in a Novel In Vitro Model of Staphylococcus aureus Biofilm

Antimicrobial Agents and Chemotherapy, 2010-10, Vol.54 (10), p.4329-4334

2010

Link zum Volltext

Verfügbarkeit prüfen

Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo Efficacy

Antimicrobial Agents and Chemotherapy, 2007-02, Vol.51 (2), p.576-582

2007

Link zum Volltext

Verfügbarkeit prüfen

High-Sensitivity MALDI-MRM-MS Imaging of Moxifloxacin Distribution in Tuberculosis-Infected Rabbit Lungs and Granulomatous Lesions

Analytical chemistry (Washington), 2011-03, Vol.83 (6), p.2112-2118

2011

Link zum Volltext

Verfügbarkeit prüfen

Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study

Clinical pharmacology and therapeutics, 2012-12, Vol.92 (6), p.696-706

2012

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and evaluation of new 1-oxa-8-azaspiro[4.5]decane derivatives as candidate radioligands for sigma-1 receptors

Bioorganic & medicinal chemistry, 2020-07, Vol.28 (14), p.115560-115560, Article 115560

2020

Link zum Volltext

Verfügbarkeit prüfen

ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib

Molecular cancer therapeutics, 2021-06, Vol.20 (6), p.1173-1182

2021

Link zum Volltext

Verfügbarkeit prüfen

Selection of a Moxifloxacin Dose That Suppresses Drug Resistance in Mycobacterium tuberculosis, by Use of an In Vitro Pharmacodynamic Infection Model and Mathematical Modeling

The Journal of infectious diseases, 2004-11, Vol.190 (9), p.1642-1651

2004

Link zum Volltext

Verfügbarkeit prüfen

Spirocyclic Sulfamides as β‑Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer’s Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies To Identify Centrally Efficacious Inhibitors

Journal of medicinal chemistry, 2012-11, Vol.55 (21), p.9224-9239

2012

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience

The European respiratory journal, 2011-10, Vol.38 (4), p.888-894

2011

Link zum Volltext

Verfügbarkeit prüfen

Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2019-08, Vol.1122-1123, p.78-82

2019

Link zum Volltext

Verfügbarkeit prüfen

Contribution of Moxifloxacin or Levofloxacin in Second-Line Regimens with or without Continuation of Pyrazinamide in Murine Tuberculosis

American journal of respiratory and critical care medicine, 2013-07, Vol.188 (1), p.97-102

2013

Link zum Volltext

Verfügbarkeit prüfen

Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1

Journal of medicinal chemistry, 2015-06, Vol.58 (12), p.5053-5074

2015

Link zum Volltext

Verfügbarkeit prüfen

Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis

Clinical infectious diseases, 2007-10, Vol.45 (8), p.1001-1007

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 491

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(472)
Mit Volltextzugriff
(397)

Publikationsform

Artikel
(491)

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(429)
Life Sciences & Biomedicine
(422)
Fluoroquinolones
(340)
Humans
(336)
Aza Compounds - Pharmacokinetics
(332)
Pharmacology & Pharmacy
(280)
Quinolines - Pharmacokinetics
(268)
Biological And Medical Sciences
(258)
Medical Sciences
(250)
Male
(233)
Pharmacology. Drug Treatments
(212)
Animals
(200)
Female
(184)
Moxifloxacin
(176)
Aza Compounds - Administration & Dosage
(151)
Adult
(144)
Anti-Infective Agents - Pharmacokinetics
(144)
Quinolines - Administration & Dosage
(139)
Middle Aged
(128)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(127)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial

Trans-Cyclooctene-Functionalized PeptoBrushes with Improved Reaction Kinetics of the Tetrazine Ligation for Pretargeted Nuclear Imaging

Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6‑Azaindole Derivative GNF2133

Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions

Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization

Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example

Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus

Kinase Inhibitors of Marine Origin

Synthesis and assessment of a maleimide functionalized BF2 azadipyrromethene near-infrared fluorochrome

Population Pharmacokinetic and Concentration-QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies

Population Pharmacokinetics of Levofloxacin, Gatifloxacin, and Moxifloxacin in Adults with Pulmonary Tuberculosis

Activities of High-Dose Daptomycin, Vancomycin, and Moxifloxacin Alone or in Combination with Clarithromycin or Rifampin in a Novel In Vitro Model of Staphylococcus aureus Biofilm

Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo Efficacy

High-Sensitivity MALDI-MRM-MS Imaging of Moxifloxacin Distribution in Tuberculosis-Infected Rabbit Lungs and Granulomatous Lesions

Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study

Synthesis and evaluation of new 1-oxa-8-azaspiro[4.5]decane derivatives as candidate radioligands for sigma-1 receptors

1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia

ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib

Selection of a Moxifloxacin Dose That Suppresses Drug Resistance in Mycobacterium tuberculosis, by Use of an In Vitro Pharmacodynamic Infection Model and Mathematical Modeling

Spirocyclic Sulfamides as β‑Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer’s Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies To Identify Centrally Efficacious Inhibitors

Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience

Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

Contribution of Moxifloxacin or Levofloxacin in Second-Line Regimens with or without Continuation of Pyrazinamide in Murine Tuberculosis

Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1

Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis

Suchergebnisse filtern